Advanced / Aggressive Approach (3.0 mL = ~10 mg/mL)
| Week | Example amount | Units (per measurement) (mL) |
|---|---|---|
| Weeks 1–2 | 5 mg (5000 mcg) | 50 units (0.50 mL) |
| Weeks 3–4 | 10 mg (10,000 mcg) | 100 units (1.0 mL) |
| Weeks 5–8 | 15 mg (15,000 mcg) | Split: 2 × 75 units (0.75 mL each) |
| Optional Weeks 9–12 | 20 mg (20,000 mcg) | Split: 2 × 100 units (1.0 mL each) |
Note: Advanced measurement (15–20 mg/day) is based on short‑term clinical trial protocols[4][5] for severe mitochondrial conditions and should only be pursued under medical supervision. Doses above 10 mg require splitting into two separate measurements at different sites. Clinical trials have not extensively evaluated SS‑31 beyond 12 weeks; extended use requires careful monitoring.
Important: This guide is for educational purposes only and is not medical advice.
How This Works
SS‑31 (elamipretide) is a cell‑permeable tetrapeptide with a unique mechanism of action targeting mitochondrial dysfunction[1]. The peptide selectively accumulates in the inner mitochondrial membrane where it binds to cardiolipin, a specialized phospholipid essential for organizing electron transport chain supercomplexes and maintaining cristae structure[2][7]. By stabilizing cardiolipin‑protein interactions, SS‑31 optimizes electron transport efficiency, reduces pathological reactive oxygen species generation, and enhances ATP synthesis in metabolically active tissues[8].
Preclinical research demonstrated that SS‑31 protects against mitochondrial dysfunction across multiple disease models including heart failure, ischemia‑reperfusion injury, neurodegeneration, chronic kidney disease, and age‑related muscle atrophy[9]. In human clinical trials, SS‑31 showed favorable safety and tolerability profiles with no dose‑limiting toxicities[4][5]. While Phase II trials in heart failure and primary mitochondrial myopathy did not meet primary efficacy endpoints, the TAZPOWER trial in Barth syndrome demonstrated significant improvements in muscle strength and six‑minute walk distance, leading to FDA accelerated approval in 2025[3][10].